-
公开(公告)号：US09393318B2
公开(公告)日：2016-07-19
申请号：US13073824
申请日：2011-03-28
申请人： Neil P. Desai , Patrick Soon-Shiong
发明人： Neil P. Desai , Patrick Soon-Shiong
IPC分类号： A01N43/02 , A61K31/335 , A01N37/00 , A61K31/21 , A61K33/24 , A61K9/14 , A61K47/48 , A61K31/337 , A61K31/555 , A61N5/10 , A61K45/06
CPC分类号： A61K47/48284 , A61K9/0019 , A61K9/14 , A61K9/146 , A61K9/5052 , A61K31/337 , A61K31/555 , A61K33/24 , A61K45/06 , A61N5/10 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , A61K2300/00
摘要： The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an effective amount of a composition comprising nanoparticles comprising docetaxel and an albumin; and b) an effective amount of a steroid.
摘要翻译： 本发明提供了通过给予a）包含包含紫杉醇和白蛋白的纳米颗粒和b）铂基药剂（例如卡铂）的组合物来治疗非小细胞肺癌（NSCLC）的方法和组合物。 本申请还提供了通过向个体施用a）有效量的包含多烯紫杉醇和白蛋白的纳米颗粒的组合物来治疗前列腺癌的方法; 和b）有效量的类固醇。
-
公开(公告)号：US08911786B2
公开(公告)日：2014-12-16
申请号：US12530188
申请日：2008-03-07
申请人： Neil P. Desai , Patrick Soon-Shiong , Vuong Trieu
发明人： Neil P. Desai , Patrick Soon-Shiong , Vuong Trieu
IPC分类号： A61K9/50 , A61K31/675 , A61K9/00 , A61K9/19 , A61K9/51 , A61K31/436 , A61K31/517 , A61K31/685 , A61K45/06 , A61K47/42 , A61N5/10 , A61N7/00
CPC分类号： A61K9/5169 , A61K9/0019 , A61K9/19 , A61K31/436 , A61K31/517 , A61K31/675 , A61K31/685 , A61K31/704 , A61K45/06 , A61K47/42 , A61N5/10 , A61N7/00 , A61K2300/00
摘要： The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.
摘要翻译： 本发明的特征在于通过施用包含雷帕霉素或其衍生物的纳米颗粒来治疗，稳定，预防和/或延缓癌症的方法。 本发明还提供包含载体蛋白质和雷帕霉素或其衍生物的纳米颗粒的组合物（例如，单位剂量形式）。 本发明进一步提供了治疗癌症的联合治疗方法，包括向个体施用有效量的包含雷帕霉素或其衍生物的纳米颗粒和第二疗法。
-
公开(公告)号：US20130071438A1
公开(公告)日：2013-03-21
申请号：US13423095
申请日：2012-03-16
申请人： Neil P. Desai , Patrick Soon-Shiong
发明人： Neil P. Desai , Patrick Soon-Shiong
CPC分类号： A61K47/42 , A61K9/0019 , A61K9/1658 , A61K9/5169 , A61K31/335 , A61K31/337 , A61K31/427 , A61K31/436 , A61K31/495 , A61K38/13 , A61K45/06 , A61L29/085 , A61L29/16 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/624 , B82Y5/00 , A61K2300/00 , C08L89/00
摘要： In accordance with the present invention, there are provided methods for treating hyperplasia in a subject in need thereof. In another aspect of the invention, there are provided methods for reducing neointimal hyperplasia associated with vascular interventional procedures. Formulations contemplated for use herein comprise proteins and at least one pharmaceutically active agent.
摘要翻译： 根据本发明，提供了在有需要的受试者中治疗增生的方法。 在本发明的另一方面，提供了减少与血管介入程序相关的新内膜增生的方法。 预期用于本文的制剂包含蛋白质和至少一种药物活性剂。
-
34.发明申请公开(公告)号：US20120177743A1
公开(公告)日：2012-07-12
申请号：US13228323
申请日：2011-09-08
申请人： Neil P. Desai , Patrick Soon-Shiong
发明人： Neil P. Desai , Patrick Soon-Shiong
IPC分类号： A61K9/14 , A61P35/00 , A61K31/337 , B82Y5/00
CPC分类号： A61K9/146 , A61K9/0019 , A61K9/5169 , A61K31/165 , A61K31/17 , A61K31/282 , A61K31/337 , A61K31/395 , A61K31/436 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/555 , A61K31/675 , A61K31/69 , A61K31/704 , A61K31/7068 , A61K31/7072 , A61K33/24 , A61K38/16 , A61K38/38 , A61K39/39558 , A61K45/06 , A61K47/42 , A61K47/643 , A61K47/6931 , A61N5/10 , A61K2300/00
摘要： The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
摘要翻译： 本发明提供了治疗增殖性疾病（例如癌症）的组合治疗方法，其包括第一疗法，其包括向个体施用有效量的纳米颗粒组合物中的紫杉烷，以及第二疗法，其可包括例如放射，外科手术 ，施用化学治疗剂或其组合。 还提供了基于节律剂给药方案向个体施用纳米颗粒组合物中的药物紫杉烷的方法。
-
公开(公告)号：US20120070502A1
公开(公告)日：2012-03-22
申请号：US13073824
申请日：2011-03-28
申请人： Neil P. Desai , Patrick Soon-Shiong
发明人： Neil P. Desai , Patrick Soon-Shiong
CPC分类号： A61K47/48284 , A61K9/0019 , A61K9/14 , A61K9/146 , A61K9/5052 , A61K31/337 , A61K31/555 , A61K33/24 , A61K45/06 , A61N5/10 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , A61K2300/00
摘要： The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an effective amount of a composition comprising nanoparticles comprising docetaxel and an albumin; and b) an effective amount of a steroid.
摘要翻译： 本发明提供了通过给予a）包含包含紫杉醇和白蛋白的纳米颗粒和b）铂基药剂（例如卡铂）的组合物来治疗非小细胞肺癌（NSCLC）的方法和组合物。 本申请还提供了通过向个体施用a）有效量的包含多烯紫杉醇和白蛋白的纳米颗粒的组合物来治疗前列腺癌的方法; 和b）有效量的类固醇。
-
公开(公告)号：US08138229B2
公开(公告)日：2012-03-20
申请号：US12910693
申请日：2010-10-22
申请人： Neil P. Desai , Patrick Soon-Shiong , Vuong Trieu
发明人： Neil P. Desai , Patrick Soon-Shiong , Vuong Trieu
CPC分类号： A61K47/42 , A61K9/0019 , A61K9/0078 , A61K9/107 , A61K9/1075 , A61K9/146 , A61K9/19 , A61K31/00 , A61K31/05 , A61K31/16 , A61K31/164 , A61K31/165 , A61K31/198 , A61K31/24 , A61K31/337 , A61K31/343 , A61K31/355 , A61K31/427 , A61K31/436 , A61K31/4745 , A61K31/7048 , A61K38/13 , A61K47/18 , B82Y5/00 , Y10S977/705 , Y10S977/773 , Y10S977/779 , Y10S977/906 , Y10S977/911 , A61K2300/00
摘要： The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
-
公开(公告)号：US20120004177A1
公开(公告)日：2012-01-05
申请号：US13038287
申请日：2011-03-01
申请人： Neil P. Desai , Patrick Soon-Shiong , Vuong Trieu
发明人： Neil P. Desai , Patrick Soon-Shiong , Vuong Trieu
CPC分类号： A61K47/42 , A61K9/0019 , A61K9/0078 , A61K9/107 , A61K9/1075 , A61K9/146 , A61K9/19 , A61K31/00 , A61K31/05 , A61K31/16 , A61K31/164 , A61K31/165 , A61K31/198 , A61K31/24 , A61K31/337 , A61K31/343 , A61K31/355 , A61K31/427 , A61K31/436 , A61K31/4745 , A61K31/7048 , A61K38/13 , A61K47/18 , B82Y5/00 , Y10S977/705 , Y10S977/773 , Y10S977/779 , Y10S977/906 , Y10S977/911 , A61K2300/00
摘要： The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
-
公开(公告)号：US20110150763A1
公开(公告)日：2011-06-23
申请号：US12971786
申请日：2010-12-17
申请人： Chunlin Tao , Qinwei Wang , Neil P. Desai , Patrick Soon-Shiong
发明人： Chunlin Tao , Qinwei Wang , Neil P. Desai , Patrick Soon-Shiong
IPC分类号： A61K51/00 , A61K31/53 , A61K31/5377 , A61K38/21 , A61K33/24 , A61K38/20 , A61P35/00 , A61P9/00 , A61P9/04 , A61P9/10 , A61P19/02 , A61P29/00 , A61P7/10 , A61P27/02 , A61P11/00
CPC分类号： C07D417/12 , C07D251/16 , C07D401/12 , C07D417/14
摘要： The invention provides for Triazine derivatives and their use to modulate protein kinase activity in a variety of conditions and diseases.
摘要翻译： 本发明提供三嗪衍生物及其在多种病症和疾病中调节蛋白激酶活性的用途。
-
公开(公告)号：US20110009337A1
公开(公告)日：2011-01-13
申请号：US12879575
申请日：2010-09-10
申请人： Vuong Trieu , Neil P. Desai , Patrick Soon-Shiong
发明人： Vuong Trieu , Neil P. Desai , Patrick Soon-Shiong
CPC分类号： C07K16/18 , A61K38/191 , C07K14/47 , C07K14/4747 , C07K14/51 , C07K14/82 , G01N2800/52
摘要： The invention provides for SPARC polypeptides with a mutation corresponding to a deletion of the third glutamine in the mature fault of the human SPARC protein, nucleic acids encoding such polypeptides, antibodies against such polypeptides, and methods of the use of such polypeptides, nucleic acids, and antibodies.
摘要翻译： 本发明提供具有对应于人类SPARC蛋白的成熟缺陷中的第三种谷氨酰胺缺失突变的SPARC多肽，编码此类多肽的核酸，针对此类多肽的抗体，以及使用此类多肽，核酸， 和抗体。
-
40.发明申请公开(公告)号：US20100183728A1
公开(公告)日：2010-07-22
申请号：US12530188
申请日：2008-03-07
申请人： Neil P. Desai , Patrick Soon-Shiong , Vuong Trieu
发明人： Neil P. Desai , Patrick Soon-Shiong , Vuong Trieu
IPC分类号： A61K9/14 , A61K31/436 , A61P35/00 , A61K31/517 , A61K31/685
CPC分类号： A61K9/5169 , A61K9/0019 , A61K9/19 , A61K31/436 , A61K31/517 , A61K31/675 , A61K31/685 , A61K31/704 , A61K45/06 , A61K47/42 , A61N5/10 , A61N7/00 , A61K2300/00
摘要： The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.
摘要翻译： 本发明的特征在于通过施用包含雷帕霉素或其衍生物的纳米颗粒来治疗，稳定，预防和/或延缓癌症的方法。 本发明还提供包含载体蛋白质和雷帕霉素或其衍生物的纳米颗粒的组合物（例如，单位剂量形式）。 本发明进一步提供了治疗癌症的联合治疗方法，包括向个体施用有效量的包含雷帕霉素或其衍生物的纳米颗粒和第二疗法。
-
-
-
-
-
-
-
-
-
搜索结果
135 条记录 (耗时 0.07 秒)
